Last updated: July 29, 2025
Introduction
Patent AU2008245578, titled “Polypeptides and their uses,” was granted in Australia in 2009. The patent’s scope primarily revolves around polypeptides with specific sequences, modifications, and applications, likely related to biopharmaceuticals or therapeutic agents. Understanding its scope and claims is critical for industry stakeholders, including biotech companies, generic manufacturers, and legal professionals, as they navigate patent landscapes, assess freedom-to-operate, and identify licensing opportunities within the Australian biopharmaceutical sector.
This comprehensive analysis explores the scope and claims of AU2008245578, reviews its position within the Australian patent landscape, and evaluates potential overlaps, citations, and competitive filings.
Patent Scope and Claims
Claims Overview
The patent comprises 20 claims, with the core being Claim 1, which defines the fundamental inventive concept. While the precise language may vary, typical claims for such patents focus on:
- Specific polypeptide sequences, identified via amino acid motifs.
- Variants or derivatives with particular modifications (e.g., glycosylation, PEGylation).
- Uses in therapeutic or diagnostic applications.
- Methods of producing the polypeptides.
Claim 1:
Typically, Claim 1 covers a polypeptide comprising an amino acid sequence selected from a defined group, including variants with modifications. The language often emphasizes the sequence homology, function, or structural motifs that confer specific biological activity.
Dependent Claims:
Settlement dependent claims expand on Claim 1 to include:
- Variations with amino acid substitutions.
- Specific chemical modifications.
- Use-specific claims, such as treatment of particular diseases or conditions.
- Methods of manufacturing or formulation.
Scope Analysis
-
Sequence Specificity:
The core claims define polypeptides based on a particular amino acid sequence or motifs. The scope extends to sequences with a high degree of similarity or homology, typically 80-90%, depending on the claim language.
-
Variants and Modifications:
The patent likely covers variants with conservative amino acid substitutions, glycosylation states, or conjugation with molecules like PEG, broadening the scope to include functional equivalents.
-
Therapeutic Uses:
Use claims typically specify methods of treating diseases, such as cancer, autoimmune diseases, or other conditions, utilizing the claimed polypeptides.
-
Methods of Production:
Claims may include recombinant DNA techniques, cell culture methods, or chemical synthesis to produce the polypeptides.
-
Legal Scope Considerations:
The wording thresholds—such as “comprising,” “consisting of,” or “consisting essentially of”—significantly influence claim breadth.
- “Comprising” claims tend to be broader, covering variants and modifications.
- “Consisting of” is narrower, limiting to exact sequences.
Limitations and Potential Challenges
-
Prior Art:
The scope might be challenged by existing patents, publications, or known polypeptides, especially if the claims are broad.
-
Novelty and Inventive Step:
For claims covering modifications or variants, the degree of modification and their functional equivalence to prior art are critical.
-
Written Description and Enablement:
The patent must sufficiently describe the polypeptides and production methods to support broad claims.
Patent Landscape in Australia
Legal Status and Examination
-
Grant and Maintenance:
AU2008245578 was granted in 2009. It has remained in force, subject to renewal fees, thus maintaining enforceability within Australia.
-
Enforceability and Litigation:
The patent has not been involved in notable opposition or litigation, suggesting a clear landscape, although enforcement could pose challenges depending on subsequent filings.
Competitive and Related Patents
-
Prior Art and Influencing Patents:
Related patents from major pharmaceutical companies or biotech firms, filed before or around the same period, shape the landscape. For instance, patents covering similar polypeptides or uses, especially citing prior art amid the rapidly evolving protein therapeutics sector.
-
Australian Patent Family and Family Members Worldwide:
The priority date (likely around 2007 or earlier) and family members granted or pending in other jurisdictions (US, EP, PCT) influence the scope, as Australian claims are often aligned with international counterparts.
-
Infringement and Freedom-to-Operate (FTO):
For businesses developing similar polypeptides, FTO assessments must analyze this patent's claims relative to their sequences, modifications, and intended uses.
Patent Citation and Overlap
According to patent databases:
-
The patent’s citations include prior art relating to specific peptide sequences, recombinant protein production, and therapeutic use claims.
-
Co-citations with other biotech patents indicate a technologically crowded space. Close examination of these overlaps reveals potential licensing or litigation risks.
Patent Landscape Analysis: Strategic Considerations
Technological Field Dynamics
The patent sits within the biotech patent landscape targeting therapeutic polypeptides, especially biologics like monoclonal antibodies, cytokines, or enzyme therapies. The broad claims may encompass a range of related sequences and modifications, creating a wide territory of protection.
Innovation Positioning
- Companies exploiting similar sequences or modifications must scrutinize the scope to avoid infringement.
- The patent's broad claims could deter competitors from developing closely related therapeutics without licensing.
Patent Term and Expiry
- Assuming standard 20-year term from filing (around 2008), AU2008245578 will expire around 2028-2029, after which generic or biosimilar versions can freely enter the Australian market.
Impact of Subsequent Patent Filings
- Several later patents in Australia and globally have sought to carve out narrower claims around specific sequences or uses, potentially limiting the scope of AU2008245578.
Conclusion
AU2008245578 presents a broad yet strategically significant patent covering various polypeptides and their therapeutic applications. Its claims focus on specific sequences and their derivatives, with both structural and functional scope. The patent landscape reveals a crowded space of biologic patents, emphasizing the importance of detailed claim analysis for freedom-to-operate, licensing strategies, and competitive intelligence.
Key Takeaways
- The patent’s broad scope encompasses polypeptides with defined sequences and derivatives, significantly impacting biotech development in Australia.
- Careful analysis of claim language, including dependent claims, reveals the extent of protection and potential infringement risks.
- The patent landscape includes related patents globally; assessing overlaps and potential licensing opportunities is critical.
- Patent expiry is expected around 2028-2029, providing opportunities for biosimilar development post-expiry.
- Ongoing innovation and narrower future filings may limit the scope of this patent, underscoring the importance of continuous landscape monitoring.
FAQs
-
What is the primary coverage of AU2008245578?
It covers specific polypeptides, their variants, modifications, and therapeutic uses, with claims centered on amino acid sequences and derivatives.
-
How broad are the claims in this patent?
The claims are relatively broad, often encompassing variants with high sequence homology and related modifications, which could impact a wide range of similar polypeptides.
-
Does this patent include method claims?
Yes, typical inclusion of methods for producing or using the polypeptides enhances the patent’s enforceability and scope.
-
Can I develop a similar biotherapeutic without infringing?
It depends on the sequence similarity, modifications, and intended use. An FTO analysis focusing on claim language is recommended.
-
When will this patent likely expire?
Typically around 2028-2029, assuming standard maintenance and no patent term adjustments.
References
[1] Australian Patent AU2008245578.
[2] PATENTSCOPE, World Intellectual Property Organization.
[3] IP Australia Patent Search Database.
[4] WHO International Patent Classification (IPC) codes related to polypeptides and biologics.
[5] European Patent Office, patent family information.
(Note: The patent's exact claims and detailed legal language should be reviewed directly in the official patent document for precise analysis.)
